Drug survival of the infliximab biosimilar (CT-P13) in paediatric patients with non-infectious uveitis.

Betül Sözeri,Esra Kardeş,Enes Salı,Deniz Çakır,Ferhat Demir

Clinical and experimental rheumatology（2021）

引用 4|浏览0

暂无评分

摘要

To our knowledge, this is the first study to assess the impact of CT-P13 treatment adherence on disease activity in children with NIU. The IFX biosimilar CT-P13 is remarkably safe and effective for the long-term treatment of paediatric NIU.

查看译文

关键词

non-infectious uveitis, children, anti-TNF-alpha, infliximab, biosimilar

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要